New drug combo aims to tame Hard-to-Treat transplant complication

NCT ID NCT06233110

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding fostamatinib to the standard drug ruxolitinib can safely help people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells attack the patient's body. The study will enroll about 30 adults and aims to find the best dose of fostamatinib to use with ruxolitinib, while also checking if the combination improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ruxolitinib and fostamatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with chronic graft-versus-host disease that does not respond to steroids.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet known. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Duke

    RECRUITING

    Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.